GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Fatty Liver Disease/Ultra-Processed Foods, MASLD and Cognitive Ageing: Nutrients | June 2026
29

Ultra-Processed Foods, MASLD and Cognitive Ageing: Nutrients | June 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated June 1, 2026
  • This review proposes a processing-centred gut–liver–brain axis, positioning MASLD as a metabolic amplifier between ultra-processed food exposure and cognitive decline.
  • Ultra-processed foods are not simply high in sugar, fat, or salt; industrial processing disrupts the food matrix, accelerates eating, displaces fibre-rich microbial substrates, and introduces additives and processing-derived compounds.
  • Higher ultra-processed food intake has been associated with hepatic steatosis, MASLD, cognitive impairment, stroke, and dementia-related outcomes, although causality remains unproven.
  • Proposed mechanisms include gut microbial dysbiosis, impaired intestinal barrier integrity, metabolic endotoxaemia, altered bile acid signalling, hepatic lipotoxicity, insulin resistance, and systemic inflammation.
  • The liver may amplify gut-derived signals and transmit inflammatory, vascular, endocrine, and metabolic effects to the brain.
  • Altered FXR and TGR5 bile acid signalling provides a biologically plausible communication pathway connecting the microbiome, liver metabolism, and neuroimmune function.
  • MASLD shares several drivers of cognitive aging, including obesity, diabetes, dyslipidaemia, endothelial dysfunction, and chronic low-grade inflammation.
  • Ultra-processed foods may also promote passive overconsumption through rapid eating, hyperpalatability, altered texture, and reduced satiety.
  • Many proposed pathways overlap with general cardiometabolic disease, making it difficult to isolate the independent effect of food processing itself.
  • Current evidence is mainly observational and mechanistic; the review does not establish that ultra-processed foods directly cause dementia or that treating MASLD prevents cognitive decline.
  • Clinically, replacing ultra-processed foods with minimally processed, fibre-rich foods may simultaneously support liver, metabolic, vascular, and cognitive health.
  • Future studies should combine dietary substitution trials with liver imaging, microbiome and metabolomic profiling, bile acid and inflammatory biomarkers, neuroimaging, and longitudinal cognitive assessment.

Bottom line: Ultra-processed foods may disrupt gut–liver–brain communication, with MASLD acting as a hepatic amplifier of metabolic and inflammatory signals relevant to cognitive aging. The concept is compelling but requires prospective mechanistic and intervention studies.

Related Q&A

30

Updated Care Pathway for MASLD Risk Stratification : Gastroenterology | Jul 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide, affecting nearly one-third of adults and a majority of...

31

PPARα Emerges as a Target in Lean MASLD : Acta Pharm Sin B | Jun 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is traditionally linked to obesity, but an increasing number of patients develop significant hepatic steatosis despite having a normal body mass...

32

Who Should Receive Resmetirom?: CGH | April 2026

Resmetirom is the first FDA-approved therapy for patients with MASH/MASLD and stage F2–F3 fibrosis, creating an urgent need for reliable noninvasive methods to identify treatment candidates. This study...

33

GLP-1RAs Linked to Lower Obesity-Related Cancer Risk : Ann Oncol | June 2026

Introduction: Obesity is a major risk factor for several malignancies, including colorectal, pancreatic, liver, endometrial, and other obesity-associated cancers (OACs). With the growing global burden of obesity, glucagon-like...

34

AI Fibrosis Mapping Redefines Risk in MetALD and ALD : Gastroenterology | June 2026

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and the recently recognized MetALD phenotype represent a rapidly expanding spectrum of chronic liver disease with overlapping metabolic and...

35

Breathomics Redefines Functional Liver Assessment : Clin Liver Dis | May 2026

Introduction Chronic Liver Disease continues to rise globally, driven predominantly by Metabolic Dysfunction-Associated Steatotic Liver Disease and alcohol-associated liver disease. Accurate evaluation of fibrosis severity and hepatic functional...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer